Advisory Research’s Cytokinetics CYTK Stock Holding History

Advisory Research’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,808	Closed	-$1.2M	–	376
2022 Q3	$1.2M	Sell	24,808 -12,075	-33%	-$581K	0.12%	134
2022 Q2	$1.45M	Sell	36,883 -2,849	-7%	-$115K	0.14%	111
2022 Q1	$1.46M	Sell	39,732 -3,086	-7%	-$110K	0.12%	145
2021 Q4	$1.95M	Buy	42,818 +9,757	+30%	+$376K	0.15%	121
2021 Q3	$1.18M	Buy	+33,061	New	+$973K	0.08%	178

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Advisory Research's CYTK Position: Q4 2022 in Review

Advisory Research sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 24,808 shares — an estimated $1.2M sold.

Advisory Research first reported a position in CYTK in Q3 2021 and held it in 5 quarters. The position peaked at $1.95M in Q4 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

Advisory Research reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
Advisory Research sold 24,808 Cytokinetics shares in Q4 2022, an estimated $1.2M.
Advisory Research first reported a position in Cytokinetics in Q3 2021 and held it in 5 quarters.
Advisory Research's Cytokinetics position peaked at $1.95M in Q4 2021.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.